Objective To perform a decision and cost-effectiveness analysis comparing four screening strategies for the antenatal diagnosis of vasa previa in singleton pregnancies. 
INTRODUCTION
Vasa previa is a placentation disorder in which fetal vessels, running erroneously through bare fetal membranes, lie on or within 2 cm of the internal cervical os as they course into the placenta 1 . If rupture of membranes and/or labor occurs, the unprotected fetal vessels can shear, causing fetal exsanguination. Prenatal ultrasound has revolutionized the diagnosis, management and subsequent outcome of pregnancies complicated by vasa previa. Prenatally diagnosed vasa previa is associated with outstanding outcome, including a 97-100% neonatal survival rate 2, 3 . However, the consequences of undiagnosed vasa previa remain catastrophic. The largest study to date, involving 155 cases of vasa previa, found neonatal survival rates among non-prenatally diagnosed cases to be only 44% 2 . A recent prospective study carried out in Australia reported a slightly higher, albeit still disturbingly low, survival rate of 60% among non-prenatally diagnosed cases 4 . The Society for Maternal-Fetal Medicine recently issued recommendations to facilitate the diagnosis and management of vasa previa, recommending transvaginal ultrasound if vasa previa is suspected 1 .
While prenatal diagnosis of vasa previa using transvaginal ultrasound with pulsed color Doppler is highly accurate with excellent sensitivity and specificity 5 , the cost-effectiveness of various vasa previa screening algorithms is largely unknown. A previous cost-effectiveness analysis investigating various vasa previa screening strategies was published by Cipriano et al. 6 in 2010. However, significant limitations of the previous study and newly published research on the topic necessitate further investigation. First, the previous authors relied heavily on 'authors' estimates' for values regarding the sensitivity and specificity of transvaginal ultrasound in the diagnosis of vasa previa. A systematic review and meta-analysis investigating the diagnostic accuracy of transvaginal ultrasound to diagnose vasa previa has been published in the interim, allowing precise calculations 5 . Furthermore, many important vasa previa studies have been published since the previous publication 3, 4, [7] [8] [9] [10] [11] [12] , including series of 60 11 , 68 3 and 96 12 cases of vasa previa, requiring an updated look at this entity, informed by contemporary literature. Therefore, in light of the out-of-date data and paucity of information regarding the cost-effectiveness of vasa previa screening strategies, the objective of this study was to perform a decision and cost-effectiveness analysis comparing vasa previa screening strategies among singleton pregnancies.
METHODS
Institutional review board exempt status was confirmed with the University of South Florida Office of Research prior to initiating the study. We constructed a decision-analytic model using TreeAge Pro 2015 software (TreeAge Software, Inc., Williamstown, MA, USA) comparing four scenarios to screen for vasa previa at the time of the routine mid-trimester (18-22 weeks' gestation) ultrasound scan ( Figure 1 ). The four screening arms were: (1) no screening; (2) ultrasound-indicated screening; (3) screening only pregnancies conceived by in-vitro fertilization (IVF); and (4) universal screening. For the no-screening arm, transvaginal ultrasound screening for vasa previa was not performed. For the ultrasound-indicated arm, screening was prompted only if a sonographically identified abnormality associated with an increased risk of vasa previa was noted during the routine anatomy scan. These abnormalities included placenta previa, low-lying placenta, marginal or velamentous cord insertion and bilobed or succenturiate lobed placenta [13] [14] [15] . This arm approximates the current recommendations of the Society for Maternal-Fetal Medicine 1 . For each strategy, the model was limited to singleton gestations and screening was defined as performing transvaginal ultrasound with pulsed color Doppler at the time of the mid-trimester ultrasound scan. Cost per quality-adjusted life year (QALY) in US$ was the primary outcome. QALY is a numerical proxy used in health economics to estimate the impact of disease on quality and quantity of life. The analysis was performed from a healthcare-system perspective with a willingness-to-pay threshold of $100 000 per QALY 16 . The incidence of vasa previa was defined with respect to the screening algorithm. The incidence of vasa previa in each screening arm was an essential part of the decision and cost analysis and was therefore embedded into each screening arm. In the no-screening, ultrasound-indicated screening and universal screening arms, the assumed baseline incidence of vasa previa was 1:2500, with a range of 1:8333 to 1:1275 17 . The incidence of vasa previa among patients who conceived using IVF was defined as 1 in 250 13, 18 . The underlying etiology of this abnormal placentation among IVF patients is poorly understood, and it is not known whether risk factors for vasa previa in the general population also apply to an IVF population. Therefore, IVF was modeled as a separate arm.
Next, sensitivity and specificity of transvaginalultrasound screening were incorporated into the model. Based on a recent systematic review, the sensitivity (or true-positive rate) of transvaginal ultrasound with pulsed color Doppler to detect vasa previa is 100%, with a reported range of 53-100%. The specificity (or true-negative rate) of transvaginal ultrasound with pulsed color Doppler is 99%, with a reported range of 99-100% 5 . It is important to note that the same transvaginal ultrasound sensitivity/specificity estimates were used in all four screening arms.
The probability of a patient undergoing mid-trimester transvaginal ultrasound screening was informed by a screening algorithm. We assumed that, in real-world circumstances, not all patients present for prenatal care and/or prenatal ultrasound. For the no-screening, ultrasound-indicated screening and universal screening arms, a no-mid-trimester ultrasound rate of 4% (range, 0-10%) was used based on available published data 6, 19, 20 . Only in the rarest of circumstances would a patient who conceived using IVF not have a mid-trimester ultrasound scan. Therefore, we estimated the no-mid-trimester ultrasound rate among IVF patients to be 1 in 1000.
For the pregnancy outcome and delivery portion of the model, we defined the rate of early fetal death (stillbirth between 20 and 27 weeks' gestation) as 3.2 per 1000 births 21 . For ongoing pregnancies, planning of delivery was informed by the presence or absence of prenatally diagnosed vasa previa. Among an undiagnosed population, approximately 0.3% of patients would plan for an early Cesarean section 22 , approximately 11% would plan for a Cesarean section in the 39 th week and 89% would plan for a vaginal delivery 6 . In a prenatally diagnosed population, it was assumed that 99.9% of the population would adhere to current recommendations to undergo late preterm delivery by Cesarean section 1 . Neonatal outcomes included late fetal death, defined as death ≥ 28 weeks' gestation and survival to birth. Perinatal mortality rates were derived from published sources, including the American College of Obstetricians and Gynecologists and Centers for Disease Control publications 21 . For pregnancies with vasa previa that experienced neonatal death, probabilities were derived from the largest-to-date vasa previa series, by Oyelese et al.
2 . An infant surviving until birth may require a blood transfusion and may not survive the neonatal period. Neonatal transfusion rates were based on published vasa previa-specific literature and a 2015 population-based neonatal intensive-care study for baseline blood transfusion estimates 2, 23 . Rates of neonatal death with early Cesarean section were based on data from the National Vital Statistics Report for mortality rates among late preterm infants, defined as infants born between 34 and 36 weeks' gestation 24 .
Maternal outcomes included the mother living with or without morbidity, or maternal death. Maternal morbidity rate following a planned vaginal or Cesarean delivery was estimated to be 0.9% or 2.7%, respectively. Maternal mortality rate was estimated to be 3.6 per 100 000 following vaginal delivery, and 13.3 per 100 000 for Cesarean section 25, 26 . Table 1 depicts the baseline probabilities, sensitivities and specificities used in the analysis. Table 2 depicts cost estimates and utilities used in the model. A thorough literature search was performed to garner accurate prices and price ranges. When 2015 prices or US$ amounts were not available, prices were adjusted for inflation and converted using present-day exchange rates. Pricing from the literature was supplemented with local Centers for Medicare and Medicaid Services (CMS) reimbursement rates. Pricing was discounted by 3% to account for individual preferences for earlier gratification.
The costs of transabdominal and transvaginal ultrasound examinations were estimated at $79.32 and $54.79 based on local Medicaid reimbursement rates for CPT codes 76 805 and 76 817, respectively. Since charge and reimbursement rates vary markedly in the USA, the sensitivity range was informed by published costs after a review of the literature 27, 28 . Of the women who had a transvaginal ultrasound examination, we assumed that a baseline rate of 1 in 2500 women would be diagnosed with vasa previa and incur costs of antepartum hospitalization. Inherent in any screening test, however, are instances of false positives and false negatives. Mindful of this, the cost of iatrogenic preterm delivery was modeled among patients with a false-positive prenatal diagnosis of vasa previa who were delivered preterm.
Patients in each screening algorithm incurred costs of transabdominal ultrasound. For patients in the IVF and universal screening arms, every patient who presented for a mid-trimester ultrasound examination incurred costs of transvaginal ultrasound screening. Patients in the ultrasound-indicated cohort incurred costs of transvaginal ultrasound if they had an ultrasound indicator that prompted screening for vasa previa. Every patient in the model who was diagnosed with vasa previa also incurred the costs of antepartum hospitalization.
As directed healthcare costs, patient time costs and costs of hospitalization prior to delivery that are specific to vasa previa are difficult to ascertain, estimates from a previous vasa previa costs publication were utilized and inflation rates were accounted for as indicated 6 . Costs for deliveries were derived from costs previously published in the literature 29 . When sufficient data were not available to inform the range for the sensitivity analysis around the point estimate for the delivery, authors' estimates were used in order to model wide variations in delivery cost. Similarly, published values for the cost of preterm birth were used to inform the model. Since costs of preterm birth vary widely based on factors such as gestational age at delivery, associated neonatal complications and geographical location, the authors estimated a wide cost range with which to run the sensitivity analysis. The QALYs used in this model are shown in Table 3 . Cipriano et al. 6 estimated QALYs in their previous publication investigating the cost-effectiveness of vasa previa screening. While advances reported in the literature necessitated that cost-effectiveness of vasa previa screening be re-examined, the QALY values presented by Cipriano et al. 6 were utilized in this publication owing to a lack of new data to update the existing published QALYs. These were also discounted at a 3% rate. The best outcome for the maternal-neonatal dyad is for the mother to live without morbidity and for the infant to survive; that combination was assigned a QALY of 17. Conversely, one of the least fortunate outcomes for the dyad is for the mother to experience morbidity and for the infant to die; this was assigned a QALY of 15.2 based on previous literature 6 .
One-way and multivariate sensitivity analyses (Monte-Carlo simulation) were performed to account for possible probability and cost ranges. Our computed simulations modeled 1000 trials and 1000 samples in each trial. A beta distribution was employed, as data suggest that this type of distribution has less bias without losing accuracy 30 . When several references were available, reported references from those sources were used for sensitivity analysis. When gaps existed in the literature, we calculated a 95% CI around the baseline estimate to perform the sensitivity analysis using Stata (Stata 13.1, College Station, TX, USA).
The number of cases of vasa previa detected and of missed and averted neonatal deaths were calculated from a theoretical cohort of 100 000 singletons for each algorithm. For example, the number of vasa previa cases detected in the ultrasound-indicated arm was calculated as follows: No. detected = 100 000 × 12.34% × 0.29% × 100%. In this equation, we assumed, based on the published literature, that 12.34% of women will have an ultrasound indicator, 0.29% of whom will have vasa previa, and that ultrasound will be 100% sensitive to detect the vasa previa 5, 6 . The number of neonatal deaths averted was calculated by multiplying the number of cases detected by 56% (i.e. the rate of neonatal death among cases of vasa previa that were not diagnosed prenatally) 2 . The value of 56% was selected as it was reported in the largest-to-date publication on vasa previa. Additionally, costs for each screening arm were calculated for the theoretical cohort by multiplying the cost per arm by 100 000 to represent the number of patients. The cost per death averted was calculated by dividing the total cost in US$ by the number of deaths averted.
RESULTS
On baseline analysis, using probabilities and costs from a thorough literature search supplemented with local CMS pricing, screening pregnancies conceived by IVF was the most cost-effective vasa previa screening strategy (Figure 2 ). The incremental cost-effectiveness ratio (ICER) (characterized by difference in cost divided by difference in effectiveness) for the IVF arm was $29186.50/QALY (Table 4) Figure 2 Cost-effectiveness analysis of four vasa previa screening strategies: no screening ( ), screening among women with an ultrasound indicator ( ), screening only in-vitro fertilization (IVF) pregnancies ( ) and universal screening ( ). Screening IVF pregnancies was most cost-effective strategy. , dominated.
was the second most cost-effective, with an ICER of $56096.77/QALY and a cost of $34608.22. While the universal screening arm was similar in price to the ultrasound-indicated arm at $34621.62, the ICER was very high at $351574.54/QALY. Sensitivity analysis revealed that these data were robust to all one-way and multivariate sensitivity analyses performed. Using Monte-Carlo simulations (1000 iterations), the cost-effectiveness acceptability curve (Figure 3) shows that IVF screening became cost effective 100% of the time at a willingness-to-pay threshold of approximately $27 500. Below this threshold, no screening was the most cost-effective strategy.
It is important to note that this model assumed antepartum hospitalization for a prenatal diagnosis of vasa previa. When we varied the sensitivity analysis to zero to account for centers that do not routinely admit Figure 3 Cost-effectiveness acceptability curve based on Monte-Carlo simulation for four vasa previa screening algorithms: no screening ( ), screening among women with an ultrasound indicator ( ), screening only in-vitro fertilization (IVF) pregnancies ( ) and universal screening ( ). Screening only IVF pregnancies for vasa previa became cost-effective at a willingness-to-pay threshold of approximately $27 500, before which no screening was most cost-effective.
patients for intensive monitoring, the results remained robust.
Estimates of outcomes in a theoretical cohort of 100 000 singleton pregnancies in the USA undergoing various vasa previa screening algorithms are depicted in Table 5 . The ultrasound-indicated and universal screening strategies detected the most cases of vasa previa (35 and 40 cases, respectively), while the no-screening and IVF-screening arms detected the fewest (two and four cases, respectively). Similarly, the ultrasound-indicated and universal screening algorithms averted the most deaths (19 and 22, respectively) , while the no-screening and IVF-screening protocols averted only one and two deaths, respectively.
The total cost of each screening algorithm ranged from 3.41 to 5.47 billion US$. However, an even wider range was noted when comparing the cost per vasa previa death averted. The lowest cost per vasa previa death averted was 157.4 million US$ in the universal screening arm, while it was significantly higher in the no-screening arm, at 3.41 billion US$.
DISCUSSION
Using a decision-analytic model, we demonstrated that screening for vasa previa is most cost-effective when performed among IVF patients. Ultrasound-indicated screening prompted by other ultrasound findings at the time of the routine anatomy scan was the second most cost-effective screening method. Both IVF and ultrasound-indicated strategies fell within contemporary willingness-to-pay thresholds, suggesting that they are both reasonable screening strategies.
Vasa previa is unique among prenatal diagnoses in that there are readily available antenatal interventions that improve the neonatal survival rate, from 44% to 97% 2 . This model identifies a target group in which prenatal screening for vasa previa can be applied in order to maximize perinatal outcome in a cost-effective manner.
Our model led us to reach similar conclusions to those of Cipriano et al. 6 . We both determined that screening at-risk populations is most cost-effective and that universal screening is not cost-effective. However, our model differed in several ways from theirs. First, Cipriano et al. included nine strategies among singleton pregnancies. While their approach was detailed, it is challenging to apply in clinical practice. Therefore, we simplified the model to include four arms for easier clinical implementation. Second, the model of Cipriano et al. was analyzed from the perspective of the Canadian publicly funded healthcare system. While there are several similarities between USA practice and the Canadian system, we conducted our analysis from a contemporaneous USA healthcare system perspective, which may capture more accurately the true cost in the USA population and guide our healthcare policy makers. Third, we incorporated the diagnostic accuracy of the screening test into this model, which, to our knowledge, has not been done previously. Modeling the sensitivity and specificity of the screening test itself is of utmost importance when performing decision analysis examining screening algorithms so that the implications of false positives and false negatives can be included. In this analysis, the consequences and subsequent costs of iatrogenic preterm birth were included in the decision arms when the prenatal diagnosis of vasa previa was a false positive.
While the present study has several strengths, there are limitations. First, the driving force of the model is a reported 44% survival rate among cases of vasa previa that are not diagnosed prenatally vs a 97% survival rate among those that are 2 . However, some of these 2 : number of cases detected × rate of neonatal death in undiagnosed cases (i.e. n × 56%). ‡Calculated as: total cost of screening strategy × number of women in cohort. §Calculated as: total cost of screening strategy/number of cases averted. ¶Calculated as 5, 6 : number of patients in cohort × proportion of population undergoing transvaginal ultrasound screening for another indication × baseline incidence of VP in unselected population × sensitivity of ultrasound (i.e. 100 000 × 0.05 × 0.0004 × 100%). **Calculated as 6 : number of patients in cohort × proportion of women at mid-gestation with ultrasound indicator × proportion of women with indicator who will have VP × sensitivity of ultrasound (i.e. 100 000 × 12.34% × 0.29% × 100%). † †Calculated as 6, 40 : (number of patients in cohort × proportion of singleton pregnancies conceived by in-vitro fertilization (IVF) × proportion of IVF pregnancies with VP × sensitivity of ultrasound) + (number of patients in cohort × proportion conceived spontaneously × proportion of population undergoing transvaginal ultrasound screening for another indication × baseline incidence of VP in unselected population × sensitivity of ultrasound) (i.e. (100 000 × 0.5% × 0.4% × 100%) + (100 000 × 99.5% × 0.05 × 0.0004 × 100%)). ‡ ‡Calculated as: number of patients in cohort × baseline incidence of VP in unselected population × sensitivity of ultrasound (i.e. 100 000 × 0.0004 × 100%). § §Calculated as 6, 40 : total number of VP cases (number of patients in cohort × proportion of singleton pregnancies conceived by IVF × proportion of IVF pregnancies with VP) + (number of patients in cohort × proportion conceived spontaneously × baseline incidence of VP in unselected population) -number of cases detected (i.e. (100 000 × 0.5% × 0.4%) + (100 000 × 99.5% × 0.0004) -n). ¶ ¶Calculated by subtracting number of neonatal deaths averted from number of deaths expected to occur if VP was not diagnosed prenatally (assuming there were 40 cases of VP, derived from 100 000 × incidence of 0.0004, with a death rate of 56%). ***Calculated by 6, 40 : subtracting number of neonatal deaths averted from number of deaths expected to occur among postnatally diagnosed VP (calculated as: (number of patients in cohort × proportion of singleton pregnancies conceived by IVF × proportion of IVF pregnancies with VP × rate of neonatal death in undiagnosed cases) + (number of patients in cohort × proportion conceived spontaneously × baseline incidence of VP in unselected population × rate of neonatal death in undiagnosed cases) (i.e. (100 000 × 0.5% × 0.4% × 56%) + (100 000 × 99.5% × 0.0004 × 56%)). data were derived from information self-reported to the Vasa Previa Foundation. Therefore, these baseline probabilities are subject to ascertainment bias and may overestimate the rate of death among cases of vasa previa that are not diagnosed prenatally. Data from a recent 1-year prospective registry from Australia found a 60% survival rate for cases of vasa previa not diagnosed prenatally 4 . This finding was incorporated into the sensitivity analyses and our results remained robust. Second, the estimates used for the diagnostic accuracy of transvaginal ultrasound with pulsed color Doppler should be discussed. A systematic review found recently that, among prospective studies, transvaginal ultrasound had a sensitivity of 100% to detect vasa previa 5 . Therefore, this point estimate was used in our analysis. However, prospective studies are subject to the Hawthorne Effect, and this 100% sensitivity value is not likely to be achieved in all centers. Therefore, a wide range (53-100%), based on a review of the literature, was utilized for probabilistic sensitivity testing and the results remained robust 6, 13, [31] [32] [33] . It is important to discuss the highly varied association between specific ultrasound indicators and vasa previa. A recent systematic review found that second-trimester placenta previa was associated with vasa previa with an odds ratio (OR) of 19 (95% CI, 6-59), while velamentous cord insertion was highly associated with vasa previa, with an OR of 672 (95% CI, 112-4034) 34 . Our model combined ultrasound indicators, but it is important to note that some individual indicators are associated more strongly with vasa previa than are others.
While this analysis was performed from a healthcare system perspective, there are costs that are unaccounted for in this model. For instance, we did not include time spent educating sonologists and sonographers. We assumed that physicians and staff who perform obstetric ultrasound are already competent at performing transvaginal ultrasound with pulsed color Doppler, but this assumption may not be true in all centers. Additionally, we used available sources for cost estimates, which are not always consistent internally. For instance, Medicaid reimbursement rates are often less than the actual costs and less than most private payers. However, many of these prices are proprietary, so the best available estimates were used in this analysis.
One additional important limitation of our model is that costs of lifelong care of an individual who survives a missed vasa previa diagnosis, subsequent medical care and parental work leave to care for the sick individual, were not included in this analysis owing to a lack of available data. This raises the significant question of whether, if said data were quantifiable, the results would change in favor of universal screening. Further research on the costs of lifelong care of an individual who survives a missed vasa previa diagnosis is needed to investigate this question.
Vasa previa screening during a time when many centers perform universal cervical-length screening should be addressed. Our model does not account for the possibility that the patient may already be undergoing transvaginal ultrasound screening. It was computed independent of universal cervical-length screening for several reasons. First, while the American College of Obstetricians and Gynecologists states that universal cervical-length screening is permissible, it is not recommended universally 35 and its cost-effectiveness is controversial 36, 37 . In an era in which this debate is ongoing and many centers do not offer universal cervical-length screening, we chose to construct our model independent of this issue.
The willingness-to-pay threshold at which ultrasoundindicated screening became cost-effective also deserves further discussion. The most appropriate willingnessto-pay threshold has been debated in the literature. The a priori willingness-to-pay threshold based on consensus was 100 000 US$ per QALY 16 . While screening IVF pregnancies was the most cost-effective in terms of cost/QALY, ultrasound-indicated screening also met our a priori willingness-to-pay threshold. Therefore, based on this, it is reasonable to conclude from our data that transvaginal screening for vasa previa should be performed among women with an IVF pregnancy and among women with an ultrasound indicator. The relatively inexpensive cost/QALY should support widespread implementation of IVF and ultrasound-indicated screening for vasa previa.
Vasa previa is a unique diagnosis in that it affords tremendous opportunity to save neonatal lives. As we balance allocation of resources with implementation of effective interventions, this model suggests that we can provide an accurate diagnosis of vasa previa and avert neonatal deaths in a cost-effective manner if we limit screening to those women with pregnancies conceived by IVF and to those with an ultrasound indicator.
